This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Edwards Lifesciences (EW) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Edwards Lifesciences (EW) Stock Moves -0.68%: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed at $111.61 in the latest trading session, marking a -0.68% move from the prior day.
Why Is Edwards Lifesciences (EW) Up 7.5% Since Last Earnings Report?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards Lifesciences (EW) Stock Moves -0.58%: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed the most recent trading day at $105.33, moving -0.58% from the previous trading session.
Here's Why You Should Retain Edwards Lifesciences (EW) Stock
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on continued strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system.
The Zacks Analyst Blog Highlights: AbbVie, Edwards Lifesciences and Johnson Controls International
by Zacks Equity Research
AbbVie, Edwards Lifesciences and Johnson Controls International are included in this analyst blog.
Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates
by Zacks Equity Research
Strong sales growth across all four product groups along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) fourth-quarter revenues.
Top Analyst Reports for AbbVie, Edwards Lifesciences & Johnson Controls
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. (ABBV), Edwards Lifesciences Corporation (EW), and Johnson Controls International plc (JCI).
Edwards Lifesciences (EW) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of -7.27% and 1.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
5 Big Cap Earnings All Stars to Watch This Week
by Tracey Ryniec
Get ready. Tesla and Microsoft are among the tech titans that will report. Can they beat again?
Why Edwards Lifesciences (EW) Might Surprise This Earnings Season
by Zacks Equity Research
Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Edwards Lifesciences (EW) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) fourth-quarter results.
Edwards Lifesciences (EW) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed at $118.26 in the latest trading session, marking a -1.83% move from the prior day.
Why Edwards Lifesciences (EW) Could Beat Earnings Estimates Again
by Zacks Equity Research
Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Edwards Lifesciences (EW) closed at $122.30, marking a -0.75% move from the previous day.
Edwards Lifesciences (EW) at 52-Week High: What's Driving It?
by Zacks Equity Research
Robust performance across the Critical Care and TAVR businesses is driving the top line for Edwards Lifesciences (EW).
The Zacks Analyst Blog Highlights: Tesla, Adobe, Merck, Edwards Lifesciences and Norfolk Southern Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tesla, Adobe, Merck, Edwards Lifesciences and Norfolk Southern Corp
Top Stock Reports for Tesla, Adobe & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Adobe Inc. (ADBE), and Merck & Co., Inc. (MRK).
Edwards Lifesciences' (EW) SAPIEN 3 With Alterra Gets FDA Nod
by Zacks Equity Research
Edwards Lifesciences' (EW) SAPIEN 3 system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation.
Zacks Investment Ideas feature highlights: Edwards Lifesciences, Mesa Laboratories and Sensus Healthcare
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Edwards Lifesciences, Mesa Laboratories and Sensus Healthcare
What History Shows Us About 2022 Market Returns
by Bryan Hayes
What to Expect From the Markets In 2022
Edwards (EW) States Long-Term Strategy, Provides 2022 View
by Zacks Equity Research
Edwards Lifesciences (EW) expects to reach significant milestones in 2022 including new product launches and progress in multiple significant clinical trials.
Here's Why You Should Retain Edwards Lifesciences (EW) Stock
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on strong third-quarter results and bullish 2021 guidance.
Edwards Lifesciences (EW) Beats on Q3 Earnings, Gross Margin Up
by Zacks Equity Research
Strong sales growth across all four products group along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) third-quarter revenues.